The use of high sensitivity methods without established cut-off points and the presence of a different, undiagnosed neoplasm with a high prevalence of BRAF mutations (e.g., melanoma and colorectal cancer) may contribute to false positivity. This evidence concerns the gene BRAF and colorectal cancer.